Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3347
Name osteosarcoma
Definition A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin.
Source DiseaseOntology.org
Alt Ids DOID:183
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma osteosarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown BMS-754807 osteosarcoma not applicable detail...
Unknown unknown Dasatinib osteosarcoma not applicable detail...
NOTCH1 I1680S MRK-003 osteosarcoma sensitive detail...
NOTCH1 E1567K MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1552G MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1552V MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1570G MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1575A MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1599M MRK-003 osteosarcoma sensitive detail...
NOTCH1 A1707T MRK-003 osteosarcoma sensitive detail...
NOTCH1 R1683W MRK-003 osteosarcoma sensitive detail...
NOTCH1 V1676I MRK-003 osteosarcoma sensitive detail...
Unknown unknown YW3-56 osteosarcoma not applicable detail...
Unknown unknown VCN-01 osteosarcoma not applicable detail...
RB1 mutant VCN-01 osteosarcoma sensitive detail...
Unknown unknown AZD7762 + VE-821 osteosarcoma not applicable detail...
Unknown unknown AZD7762 + Hydroxyurea + VE-821 osteosarcoma not applicable detail...
CBLC dec exp Olaparib osteosarcoma predicted - sensitive detail...
SMO dec exp SANT1 osteosarcoma predicted - sensitive detail...
Unknown unknown WZ4003 osteosarcoma not applicable detail...
Unknown unknown HTH-01-015 osteosarcoma not applicable detail...
Unknown unknown V158411 osteosarcoma not applicable detail...
Unknown unknown Pembrolizumab osteosarcoma not applicable detail...
Unknown unknown Prexasertib osteosarcoma not applicable detail...
Unknown unknown Gemcitabine + Sirolimus osteosarcoma not applicable detail...
Unknown unknown Capmatinib osteosarcoma not applicable detail...
Unknown unknown NKTR-214 osteosarcoma not applicable detail...
STAG2 negative Cisplatin osteosarcoma predicted - resistant detail...
PDGFRA D846V Sorafenib osteosarcoma predicted - sensitive detail...
Unknown unknown DSP-0509 osteosarcoma not applicable detail...
Unknown unknown SP-2509 osteosarcoma not applicable detail...
AKT1 amp MK2206 osteosarcoma sensitive detail...
BRAF G469V Trametinib osteosarcoma no benefit detail...
Unknown unknown Saracatinib osteosarcoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Active, not recruiting
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01759303 Phase II Pazopanib Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung Terminated
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Recruiting
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Active, not recruiting
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Active, not recruiting
NCT02357810 Phase II Pazopanib + Topotecan Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Active, not recruiting
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Active, not recruiting
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting
NCT02470091 Phase II Denosumab Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Active, not recruiting
NCT02487979 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Completed
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed
NCT03006848 Phase II Avelumab A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Active, not recruiting
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Active, not recruiting
NCT03190174 Phase Ib/II Nab-Rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting
NCT03320330 Phase Ib/II Pepinemab VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Active, not recruiting
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting
NCT03628209 Phase Ib/II Azacitidine + Nivolumab Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Recruiting
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Recruiting
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Recruiting
NCT03900793 Phase I Losartan + Sunitinib Losartan + Sunitinib in Treatment of Osteosarcoma Recruiting
NCT03960177 Phase I Glucarpidase Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma Recruiting
NCT04040205 Phase II Abemaciclib Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Recruiting
NCT04154189 Phase II Etoposide + Ifosfamide Etoposide + Ifosfamide + Lenvatinib A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma Recruiting
NCT04183062 Phase II BIO-11006 + Docetaxel + Gemcitabine BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases Recruiting
NCT04417062 Phase II AZD6738 + Olaparib Olaparib With Ceralasertib in Recurrent Osteosarcoma Not yet recruiting
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Not yet recruiting